Sexually transmitted diseases constitute a great group of diseases
produced by different etiological agents, that they have in common that
sexual relations are their principal line of transmission. This fact
confers them the special connotation for their control we need to know and
acting upon relations and sexual conducts of people. In the last 20 years,
in our country has taken place a situation that complicates still mo...
Sexually transmitted diseases constitute a great group of diseases
produced by different etiological agents, that they have in common that
sexual relations are their principal line of transmission. This fact
confers them the special connotation for their control we need to know and
acting upon relations and sexual conducts of people. In the last 20 years,
in our country has taken place a situation that complicates still more the
actions of health about these diseases. While the liberalization in
sexual relations becomes evident, with frequent changes of couples, the
risk between the population is biggest, mainly between the young, in
addition prejudices and limitations keep in the moments in which it proves
to be necessary to talk about them. Possibly for these same circumstances,
Sexually Transmitted Diseases constitute a serious problem of health all
over the world. We have a program that tries to combine the real existent
possibilities in the country, as of the present moment, as to diagnosis,
treatment and epidemiologic handling of the cases, taking into account the
most frequent diseases and the fact that they can produce bigger
complications, but mainly those about which we consider more important in
our area of health, specifically Syphilis and Blennorrhagia.
AIDS collects every day more human lives, the sexual
irresponsibility, poorness, the economic crises, they have converted in
allies of the mortal pandemic. But I wonder: When we find the vaccine to
combat this virus, would have we the possibility of putting it at the
disposal of the million sick persons around the world and whose economic
condition is very bad?
The distribution of the antiviral medications at present i...
AIDS collects every day more human lives, the sexual
irresponsibility, poorness, the economic crises, they have converted in
allies of the mortal pandemic. But I wonder: When we find the vaccine to
combat this virus, would have we the possibility of putting it at the
disposal of the million sick persons around the world and whose economic
condition is very bad?
The distribution of the antiviral medications at present is limited, the
economic restrict the possibilities for poor people, then when we will
have the vaccine, the international organizations of health will have to
make a great effort to achieve that the vaccine against the HIV is the
solution of disease really, and no the agony of other ones that they will
not be able to come over the vaccine.
On Cuba we notify between 40 and 50 thousand cases annually only of
Sifilis, Blenorragia and Condylomatum Acuminatum, with tendencies to
the increment for years.
In order to get modification of the tendencies and reduction of the
transmission of these diseases, we take promotional actions of health
directed to establish habits and sexual safe or minor- risk conducts, but
that only we have impact in the long term, becaus...
On Cuba we notify between 40 and 50 thousand cases annually only of
Sifilis, Blenorragia and Condylomatum Acuminatum, with tendencies to
the increment for years.
In order to get modification of the tendencies and reduction of the
transmission of these diseases, we take promotional actions of health
directed to establish habits and sexual safe or minor- risk conducts, but
that only we have impact in the long term, because it is well known that
it does not prove to be easy to modify these behavioral aspects of the
life of people. These educational and promotional actions from health are
common for all the Sexually Transmitted Diseases, including the HIV for
that reason the actions played inside a specific program benefit the
prevention in the group.
With this method we exercise a better control and we raise knowledge and
we supply of tools that they avoid the propagation of these diseases.
Gaydos1 highlights the barriers to discussing sexual health issues
openly and teenagers' lack of awareness of the high prevalence of STIs and
potential adverse reproductive sequelae. Addressing these barriers is one
solution to the 'Hidden Epidemic' of STIs. In the UK as in the USA, STI
rates remain highest among sexually active teenagers, particularly those
from deprived inner city areas and black ethnic minority groups....
Gaydos1 highlights the barriers to discussing sexual health issues
openly and teenagers' lack of awareness of the high prevalence of STIs and
potential adverse reproductive sequelae. Addressing these barriers is one
solution to the 'Hidden Epidemic' of STIs. In the UK as in the USA, STI
rates remain highest among sexually active teenagers, particularly those
from deprived inner city areas and black ethnic minority groups.2 Ensuring
a high standard of Sex and Relationships Education (SRE) may contribute to
reducing risky sexual behaviour.3
During December 2010 for a medical student research project, we
conducted a cross-sectional questionnaire survey to investigate high-risk
teenagers' experience of SRE. Consecutive male and female patients aged
14-19 years attending Adolescent Genito-Urinary Medicine Clinics in
Wandsworth, South London were asked to complete a questionnaire survey on
their experience of SRE at school. The questionnaire asked if they had
received SRE, the topics covered, timings, perceptions of SRE and where
sexual health information was accessed. Data were entered and analysed
using SPSS.
The response rate was 94% (97/103). The mean age of responders was 16
years (range 14-19), and 69% were female. Of 97 responders, 41% described
their ethnicity as white, 49% black and 10% as other ethnic group.
Although 99% had received SRE at school, 69% said the quality of SRE was
average or poor. Median age at first SRE in school was 11 years (range 5-
16). Teenagers reported a desire to be taught earlier (by aged 12) about
menstruation, teenage pregnancy, STIs, HIV and relationships. The
biological topics, menstruation, contraception and STIs were found the
most useful at school, but 30% said they were not taught about emergency
contraception. Sexual health clinics, school lessons and friends were the
main sources of sexual health information (91%, 77% and 74%,
respectively). Only 30% felt comfortable accessing information from
school. Over half the respondents accessed the media and internet which
may not be reliable.
This survey found that most of these high risk, sexually active
teenagers had received some SRE, but the standard was inconsistent and
often too late. It suggests that in the UK, SRE should be taught as a
statutory part of the national curriculum. We agree with Gaydos that
special education tools such as effective SRE are needed to tackle the
epidemic of STIs. In Holland SRE starts at the age of five and the country
has the lowest teenage pregnancy rate in Europe.4 Providing SRE earlier at
school backed up by easily accessible information from sexual health
clinics might help to decrease STI rates among teenagers in the UK, North
America and elsewhere.
Aneeta Kaneshanathan, Katia Prime, Phillip E Hay and Pippa Oakeshott
ACKNOWLEDGEMENTS
We thank staff at Courtyard Clinic, St George's Hospital London - Wendy
Majewska and Charlotte Jackson for their help with this project.
Population Health Sciences and Education, St George's University of
London, London, SW17 ORE, UK
Correspondence to: A Kaneshanathan
Email: m0700538@sgul.ac.uk
REFERENCES
1. Gaydos. STI management and control in North America IUSTI region.
Sex Transm Infect 2011;87:ii2-ii6.
2. Health Protection Agency. Acute STI diagnoses by PCT of residence,
2009 (England). Health Protection Report Vol 4 No. 34 - 27 August 2010.
3. Wellings K, Nanchahal K, Macdowall W, McManus S, Erens B, Mercer
C, Johnson A, Copas A, Korovessis C, Fenton K, Field J. Sexual behaviour
in Britain: early heterosexual experience. Lancet 2001; 358, 1843-1850.
4. UK Youth Parliament. SRE - Are you getting it? London; June 2007
STDs were commonly known as venereal diseases : Veneris is the Latin
genitive form of the name Venus , the Roman goddess of love. Social
disease was another euphemism.
Public health officials originally introduced the term sexually
transmitted infection , which clinicians are increasingly using alongside
the term sexually transmitted disease in order to distinguish it from the
former. According to Ethiopian AIDS Resourc...
STDs were commonly known as venereal diseases : Veneris is the Latin
genitive form of the name Venus , the Roman goddess of love. Social
disease was another euphemism.
Public health officials originally introduced the term sexually
transmitted infection , which clinicians are increasingly using alongside
the term sexually transmitted disease in order to distinguish it from the
former. According to Ethiopian AIDS Resource Center FAQ - Are sexually
transmitted infections (STIs) different from sexually transmitted diseases
(STDs)? , "Sometimes the terms STI and STD are used interchangeably. This
can be confusing and not always accurate, so it helps first to understand
the difference between infection and disease. Infection simply means that
a germ, virus , bacteria , or parasite that can
cause disease or sickness if present inside a person's body. An infected
person does not necessarily have any symptoms or signs that the virus or
bacteria is actually hurting his or her body; they do not necessarily feel
sick. A disease means that the infection is actually causing the infected
person to feel sick, or to notice something is wrong. For this reason, the
term STI which refers to infection with any germ that can
cause an STD, even if the infected person has no symptoms is a
much broader term than STD. " The distinction being made, however, is
closer to that between a colonization and an infection , rather than
between an infection and a disease .
Specifically, the term STD refers only to infections that are causing
symptoms . Because most of the time people do not know that they are
infected with an STD until they start showing symptoms of disease , most
people use the term STD, even though the term STI is also appropriate in
many cases.
Moreover, the term Sexually Transmissible Disease is sometimes used since
it is less restrictive in consideration of other factors or means of
transmission. For instance, meningitis is transmissible by means of sexual
contact but is not labeled as an STI because sexual contact is not the
primary vector for the pathogens that cause meningitis. This discrepancy
is addressed by the probability of infection by means other than sexual
contact . In general, an STI is an infection that has a negligible
probability of transmission by means other than sexual contact, but has a
realistic means of transmission by sexual contact (more sophisticated
means blood transfusion , sharing of hypodermic needles are not taken into account). Thus, one may presume that, if a
person is infected with an STI, e.g., chlamydia , gonorrhea , genital
herpes , it was transmitted to him/her by means of sexual contact.
The English language has short words for two of the most common: "pox" (
syphilis ) and "the clap" ( gonorrhea ).
Your recent major article by Harryman et al 1 assessed the
performance of Aptima Combo 2 (AC2) confirmed by Aptima GC (AGC) versus
culture and concluded that AC2 with AGC confirmation performed well at
genital and extra-genital sites for detection of GC. Culture with
transport swabs was found to perform poorly for asymptomatic men,
symptomatic and asymptomatic women and at extra-genital sites. The authors
conclude that c...
Your recent major article by Harryman et al 1 assessed the
performance of Aptima Combo 2 (AC2) confirmed by Aptima GC (AGC) versus
culture and concluded that AC2 with AGC confirmation performed well at
genital and extra-genital sites for detection of GC. Culture with
transport swabs was found to perform poorly for asymptomatic men,
symptomatic and asymptomatic women and at extra-genital sites. The authors
conclude that consideration should be given into how best to optimise GC
culture in settings where direct plating is not feasible.
We strongly agree with them and are pleased to find the accumulating
evidence for the performance benefits of AC2 confirmed with AGC. They
mentioned that studies by Moss et al and Lavelle et al concluded that AC2
GC positives were likely to be true positives based on culture and partner
data, but point out that both studies confirmed their positives only by
repeating the same assay. However we in our later study confirmed all GC
positives by AC2 by retesting residual sample in the AGC assay 2.
In our study we looked retrospectively at laboratory dual testing
data between August 2006 and April 2008 and reviewed case-notes of all
patients with a positive result for GC (culture or AC2 confirmed by AGC ).
Testing was at Macclesfield genitourinary medicine (GUM) clinic (3589
dual NAATS samples from 1930 females and 2470 dual NAATS sample from 1867
males) and in the corresponding community served by the 'Team Chlamydia'
office of the National Chlamydia Screening Programme (1549 male and 7934
female samples). Of the total of 15, 542 tests performed only one was
positive for GC by AC2 but unconfirmed by AGC. There was no culture
positive but AC2 negative result in any of our patients tested by both
methods. At the GUM clinic, 6 (19%) male cases and 4 (25%) female cases
would have been missed if tested only by culture. Of the 6 males, 3 were
positive at extra-genital sites (pharyngeal swabs) only.
In the community 23 young females would have gone undiagnosed and
untreated for GC infection if tested only for chlamydia infection.
The overall positivity for GC in the GUM clinic was 1.3%, the true
prevalence being 0.9% (after excluding already diagnosed cases referred
from the community and those presenting as contacts) and that in the
community was 0.4%.
Culture alone must now be considered unfit for testing asymptomatic
patients and inadequate to meet the challenge of detecting and managing
the large number of cases that are to be found outside of GUM settings 3.
Following the recent Guideline 4- that GC should always be treated with a
two antibiotic combination - GC culture may retain its importance for
survey and monitoring of changes in antibiotic-susceptibility patterns but
becomes less essential as a test for every individual patient.
Moncado et al 5 evaluated 3 of the CDC approaches for confirming GC
positive NAAT results and concluded that confirmatory testing was not
warranted for genital specimens. With our results and those of Harryman et
al and as more evidence accumulates confidence may grow that, for AC2 at
least, confirmation is unnecessary.
REFERENCES
1. Harryman L, Scofield S, Macleod J, et al. Comparative performance
of culture using swabs transported in Amies medium and the Aptima Combo2
nucleic acid amplification test in detection of Neisseria gonorrhoeae from
genital and extra-genital sites: a retrospective study. Sex Transm Infect
2011; doi;10.1136/sextrans-2011-050075
2. Mahto M, Zia S, Ritchie D, et al. Diagnosis, management and
prevalence estimation of gonorrhoea: influences of Aptima Combo 2 assay
with alternative target confirmation. International Journal of STD &
AIDS 2009;20:315-319
3. Skidmore S, Copley S, Cordwell D et al. Positive nucleic acid
amplification tests for Neisseria gonorrhoeae in young people tested as
part of the National Chlamydia Screening Programme. International Journal
of STD & AIDS 2011; 22: 398-399
4. Bignell C, FitzGerald M. UK national guideline for the management
of gonorrhoea in adults, 2011. International Journal of STD & AIDS
2011;22:541-547
5. Moncada J, Donegan E, Schachter J. Evaluation of CDC- Recommended
approaches for confirmatory testing of positive Neisseria gonorrhoeae
nucleic acid amplification test results. J Clin Microbiol 2008;46:1614-
1619.
Stephanie Dellicour 1,2,3 , Florence Diemo4, Kayla Laserson2,3, Feiko
ter Kuile1, Meghna Desai2,3
1. Child and Reproductive Health, Liverpool School of Tropical Medicine,
UK
2. Kenya Medical Research Institute (KEMRI), Center for Global Health
Research (CGHR), Kisumu, Kenya
3. Centers for Disease Control and Prevention (CDC), Atlanta, USA
4. Rarieda District Medical Officer for Health (DMOH), Nyanza Province,
Kenya
Stephanie Dellicour 1,2,3 , Florence Diemo4, Kayla Laserson2,3, Feiko
ter Kuile1, Meghna Desai2,3
1. Child and Reproductive Health, Liverpool School of Tropical Medicine,
UK
2. Kenya Medical Research Institute (KEMRI), Center for Global Health
Research (CGHR), Kisumu, Kenya
3. Centers for Disease Control and Prevention (CDC), Atlanta, USA
4. Rarieda District Medical Officer for Health (DMOH), Nyanza Province,
Kenya
We read with great interest the article by Otieno-Nyunya and
colleagues1. The authors report low prevalence of syphilis 1.8% (95% CI
1.5% to 2.1%) as detected through the Kenya AIDS Indicator Survey (KAIS)
for 2007. The authors suggest these findings indicate that elimination of
syphilis is a possibility in Kenya. They also show that syphilis testing
is common among women attending antenatal care (ANC) clinics and that
recent estimates suggest that prevalence of syphilis among pregnant women
has declined to less than 1%. Despite this success, we wish to highlight
that there may still be pockets of high syphilis prevalence in Kenya.
As part of an ongoing observational study among pregnant women
attending ANC in Asembo, Rarieda District, western Kenya, we observed an
unexpected high prevalence of syphilis of 11.5% (32/282). The study
participants are women living in 33 villages within a 5km radius of the
study health facility coming for routine antenatal care, representing the
general population in this area (i.e. not selected according to any health
related criteria). Antenatal profile laboratory tests are performed by the
facility laboratory (supplied by the Kenya Medical Supplies Agency (KEMSA)
or Mission for Essential Drugs and Supplies (MEDS)) and are available free
of charge for study participants. Overall 282 first ANC clients have been
tested for syphilis during the period between February and September 2011.
Different tests have been used during that period depending on the
supplies provided as follows: VDRL (from Euromedi Equipment LTD, UK) was
used from February to beginning of May 2011 with an associated syphilis
prevalence of 8% (11/143), treponemal only rapid test (Eurostrip from
Euromedi Equipment LTD, UK) from May to July 2011 with a prevalence of
17% (17/101) and another treponemal only rapid test (from Acon
Laboratories, USA) from August to September 2011 with a prevalence of 11%
(4/38). Note that the latter two treponemal rapid tests show higher
prevalence as these reflect both past and current infections. The
prevalence of HIV infection in this population of pregnant women is 28% by
rapid test (Determine from Alere Medical Company, Japan and Bioline
Standard Diagnostics Inc., South Korea, with Uni-Gold Trinity Biotech PLC,
Ireland as the tie-breaker).
All the 32 women testing positive for syphilis were asymptomatic and
many did not get the prescribed treatment due to costs (one dose of
Benzathine Penicillin and Erythromycin cost Ksh 300 equivalent to ~USD 3);
13 reported no treatment and 11 reported incomplete treatment out of 27
with follow up data. Untreated pregnancies can result in adverse outcomes
due to syphilis, such as spontaneous abortion or stillbirth, neonatal
death, low birth weight/premature birth or congenital infection of the
newborn in up to 80% of cases.23 Furthermore due to the stigma associated
with sexually transmitted infections (STIs), even if pregnant women get
treated, their partners most often will not.
Similar high prevalence has since been reported at the district
level. Collated data from monthly health facility reports in the district
show 23% prevalence of syphilis for 2009/2010 and 12% for 2010/2011 (DMOH
personal communication). These high rates remained unreported as syphilis
is no longer a notifiable disease in Kenya since 2009. Furthermore, the
prominence of HIV indicators at district and provincial level reporting
may also be partly responsible for other STIs being under-reported and
overlooked. The prevalence of syphilis, and of STIs in general, is higher
in antenatal clients compared to the general population as these represent
the sexually active group. Whereas, a few previous studies have shown the
prevalence of syphilis among pregnant women in Kenya to range from 3% to
4%,3 4 Otieno-Nyunya et al report a syphilis prevalence of less than 1%
in recently pregnant women from the KAIS survey and noted the limitation
from this small sub-sample (which included only 1 positive pregnant
woman).
The high rate observed in Rarieda district highlights the fact that
there might be hot spots which will need to be managed in order to achieve
elimination. Screening pregnant women for syphilis provides an important
means to monitor population prevalence and of identifying pockets of high
syphilis prevalence. In 1940s, western European countries introduced
antenatal syphilis screening and management programmes as part of the
strategy for syphilis elimination.5 However implementation of antenatal
screening for syphilis in low income countries is often poor due to
irregular procurement of tests and the additional cost of the syphilis
test incurred by ANC clients. Otieno-Nyunya et al report that antenatal
syphilis screening is common in Kenya. However, there is considerable
variation in the uptake of syphilis testing. In Rarieda district, less
than 10% of first ANC clients are tested for syphilis as reported by the
health facilities in 2009 and 2010. New simple and user-friendly, point-of
-care rapid diagnostic tests for syphilis provide an opportunity to scale-
up antenatal syphilis screening even in facilities without laboratory
capacity.
The low country-wide population prevalence detected by KAIS is
encouraging, but should be interpreted carefully. It will be important to
enhance antenatal syphilis screening both for sentinel surveillance and to
reduce the incidence of adverse pregnancy outcomes attributable to
syphilis as well as congenital syphilis. Maternal syphilis screening and
treatment is among the most cost-effective public health interventions. 6
The effect of the antenatal syphilis screening program could be improved
through earlier antenatal attendance, as well as expansion to cover free
syphilis treatment and explicit efforts to encourage partner notification
and treatment. Operational barriers including procurement inconsistencies
with syphilis test types and stock outs of both tests and treatment should
be addressed. Additionally, more efforts are needed to increase public
and health professional awareness of the potential serious consequences of
syphilis. All these efforts will be required for disease control and
eventually elimination. More emphasis should also be given to HIV
uninfected ANC clients who don't currently benefit from free care and
treatment. As argued previously, there should be stronger integration
between syphilis screening and HIV-PMTCT programmes which have higher
level of funding and political commitment. 7 The Kenyan Division of
Reproductive Health would benefit from additional support to strengthen
national STI program and policies for the antenatal population.
References
1. Otieno-Nyunya B, Bennett E, Bunnell R, Dadabhai S, Gichangi AA, Mugo N,
et al. Epidemiology of syphilis in Kenya: results from a nationally
representative serological survey. Sex Transm Infect 2011;87(6):521-25.
2. Kamb ML, Newman LM, Riley PL, Mark J, Hawkes SJ, Malik T, et al. A road
map for the global elimination of congenital syphilis. Obstet Gynecol Int
2010;2010.
3. Temmerman M, Gichangi P, Fonck K, Apers L, Claeys P, Van Renterghem L,
et al. Effect of a syphilis control programme on pregnancy outcome in
Nairobi, Kenya. Sex Transm Infect 2000;76(2):117-21.
4. Buve A, Weiss HA, Laga M, Van Dyck E, Musonda R, Zekeng L, et al. The
epidemiology of gonorrhoea, chlamydial infection and syphilis in four
African cities. AIDS 2001;15 Suppl 4:S79-88.
5. Deperthes BD, Meheus A, O'Reilly K, Broutet N. Maternal and congenital
syphilis programmes: case studies in Bolivia, Kenya and South Africa. Bull
World Health Organ 2004;82(6):410-6.
6. Vickerman P, Peeling RW, Terris-Prestholt F, Changalucha J, Mabey D,
Watson-Jones D, et al. Modelling the cost-effectiveness of introducing
rapid syphilis tests into an antenatal syphilis screening programme in
Mwanza, Tanzania. Sex Transm Infect 2006;82 Suppl 5:v38-43.
7. Watson-Jones D, Oliff M, Terris-Prestholt F, Changalucha J, Gumodoka B,
Mayaud P, et al. Antenatal syphilis screening in sub-Saharan Africa:
lessons learned from Tanzania. Trop Med Int Health 2005;10(9):934-43.
In a recent letter Oakeshott 1 cited the lack of data on the
prevalence of Trichomonas vaginalis (TV) in young women in the UK. In
their own pilot study of 183 stored self -taken vaginal samples from
multi-ethnic London female students in age group of 16-27, 2 (1.1%, 95%
CI 0.1%-3.9%) were positive by an in house multiplex real-time PCR test.
We in Macclesfield, UK, recently conducted a prospective pilot study to
ga...
In a recent letter Oakeshott 1 cited the lack of data on the
prevalence of Trichomonas vaginalis (TV) in young women in the UK. In
their own pilot study of 183 stored self -taken vaginal samples from
multi-ethnic London female students in age group of 16-27, 2 (1.1%, 95%
CI 0.1%-3.9%) were positive by an in house multiplex real-time PCR test.
We in Macclesfield, UK, recently conducted a prospective pilot study to
gain female positivity data with the use of a Nucleic acid amplification
test (NAAT), the Gen-Probe Aptima TV assay (ATV) in three different
clinical settings - community clinics, genitourinary (GU) medicine clinic
and its satellite prison GU medicine service2.
All women at the three different settings were offered an ATV test on the
residual portions of the Aptima transport medium from any vulvovaginal
swabs or first catch urine samples that had been collected for a routine
Aptima Combo 2 Chlamydia/Gonorrhoea test. Women below the age of 16 were
excluded. Positivity rates at community clinics and GU medicine, were
respectively 0/382 (0%) and 3/358 (0.8%, CI 0% - 1.7%). Positivity was
significantly higher, 29/269 (10.8%, CI 7.1% - 14.5%) - Odds Ratio 14.3
(4.11 < OR < 59.55) - in those tested at the prison. This compares
to overall chlamydia positivity rates of 4.6% in the community, 6.3% in GU
medicine and 5.3% in the prison and overall gonorrhoea positivity rates of
0.09%, 0.2% and 0.2% respectively.
For the 32 ATV positive women, the mean age was 30.6 (range 19 to 48)
years, 27 were White British/Irish, 2 Chinese and 3 were of Black African
origin, 9 (28%) were symptomatic and 3/32 (9.4%) had concomitant
chlamydia. No woman had concomitant gonorrhoea.
We also conducted a questionnaire survey of English GU medicine clinics
and obtained data from the United Kingdom Health Protection agency (HPA)
for England. Both demonstrated the large variation in case rates by region
and testing methods employed. Higher rates were seen in women, in prison
GUM services and in London GUM clinics.
Perry et al3 in a recent ongoing study in a London GUM clinic using the
ATV assay on residual routine samples taken for CT /GC in women found a
positivity rate of 11.8% (36/305, age range for both men and women 24-39
years ), 81% of whom were symptomatic. They concluded that ATV improved
clinical detection by 33% over wet mount microscopy and did not reveal as
many missed diagnoses as predicted. They speculated that this was because
the majority were symptomatic and that the ATV assay may have more
important role in community based screening of asymptomatic women or men.
Consideration of current standards of care may mean more tests should
be offered to a wider population. Monitoring positivity in defined
patient groups where the test might be introduced should lead to cost-
effective application and also help to clarify the levels of asymptomatic
carriage. Use of the new CE marked ATV assay in some populations is
warranted so as to lead to proper detection and treatment of TV and also
possibly the prevention of other co-transmitted infections, such as HIV.
REFERENCES
1. Oakeshott P, Ahmed J, Hay PE et al. Trichomonas vaginalis among multi-
ethnic female UK students. Sex Trans Infect 2011;doi:10.2236/sextrans-2011
-050061
2. Mahto M, Evans-Jones J, Zia S et al Finding cases of Trichomonas
vaginalis infection in England. International Journal of STD and AIDS
2011;22:471-473
3. Perry M, Benzie A, Erasmus K et al Clinical utility of a nucleic acid
amplification test for Trichomonas vaginalis in a targeted urban
genitourinary medicine clinic population. Oral Presentation, British
Association for Sexual Health and HIV (BASHH) Spring Meeting, Gateshead,
11th-13th May 2011.
In the paper from the HPA on cost of treatment of genital warts Woodhall et al come to the extraordinary conclusion that in the UK genital warts only costs £94 per case.1 Why they strip out all the 'on costs' of an NHS visit is hard to understand. All the other studies referred to, are seen as so methodologically flawed that comparison is impossible. One particular study, not referred to, deserves particular mention.2 In this s...
In the paper from the HPA on cost of treatment of genital warts Woodhall et al come to the extraordinary conclusion that in the UK genital warts only costs £94 per case.1 Why they strip out all the 'on costs' of an NHS visit is hard to understand. All the other studies referred to, are seen as so methodologically flawed that comparison is impossible. One particular study, not referred to, deserves particular mention.2 In this study published in 2003, by 2 (CJNL, GK) of the same authors, it was estimated that genital warts cost just over £200 in 'direct costs'. When the patient costs were added in the estimate came to over £500 per case at 2003 prices. Even more significantly this trial excluded the 'heart sink' wart patients we all know and dread in clinic. "Exclusion criteria included known HIV infection or immunosuppression, homosexual men with perianal warts, total lesional area >400 mm2, any individual lesion with an area of >100 mm2, intrameatal or vaginal warts, ulcerative or inflammatory STDs of the anogenital region, and pregnancy........Its size, design, and multicentre nature make it likely that the results are a reasonable reflection of treatment outcomes for first episode genital warts in clinical practice."
Does it really matter that there is one estimate that is only £94 per case? Well yes it does. As chair of BMA Dermatovenereology committee I wrote to Ann Milton MP minister of public health asking her how the review of the HPV vaccine contract would be decided and her reply indicated that recent information from the HPA on economic evaluation would be key. If yet again the NHS costs of HPV 6 and 11 are minimised, the bivalent vaccine need only be slightly cheaper than the quadrivalent vaccine to once again win the contract. If the review considers the true cost effectiveness i.e. genital wart management in GUM and general practice, adult and juvenile respiratory papilloma, abnormal smears due to 6 and 11 and early (within 3 or 4 years) return on investment as 15 and 16 year olds stop turning up with warts to clinics, the quadrivalent vaccine would be chosen. If only the bivalent is used there will be no savings until 13 years later when these 12 year olds eventually have their first smear at age 25.
Australia has shown that vaccination is likely to eliminate genital warts soon, as even males have seen a dramatic reduction from vaccination of young women with the quadrivalent vaccine.3
Indeed the UK is the only developed country in the world (apart from Holland) to be exclusively using the bivalent vaccine. Even some undeveloped countries like Rwanda are doing a national vaccination programme with the quadrivalent vaccine. So within a few years the sexual health of teenagers in Rwanda will be better than that in the UK? Is that our legacy?
References
1. Woodall SC, Jit M, Soldan K et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect (2011). doi;10.1136/sextrans-2011-050073
2. Lacey C J N, Goodall RL, Ragnarson Tennvall G et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003;79:270-275
3. Christopher K Fairley, Jane S Hocking, Lyle C Gurrin, et al. Rapid decline in presentations for genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women. Sex Transm Inf. doi:10.1136/sti.2009.037788
Conflict of Interest:
I have received lecture fees and sat on advisory boards for GSK ( who make Cervarix - the bivalent vaccine) and Sanofi Pasteur MSD (who make Gardasil - the quadrivalent vaccine) I write prescriptions for £0.3 million worth of GSK drugs per year.
Dear Editor:
I would like to spot two obvious errors at the data extraction in the article by Kalichman et al on the systematic review of the prevalence of sexually transmitted coinfections in people living with HIV/AIDS. First, in Table 1 the study site of the Reference 31 by our study group, was located in Taiwan, instead of China. Second, it is clearly listed in the text of the Reference 31 that 79.7% of the participants had r...
Dear Editor:
I would like to spot two obvious errors at the data extraction in the article by Kalichman et al on the systematic review of the prevalence of sexually transmitted coinfections in people living with HIV/AIDS. First, in Table 1 the study site of the Reference 31 by our study group, was located in Taiwan, instead of China. Second, it is clearly listed in the text of the Reference 31 that 79.7% of the participants had received highly active antiretroviral therapy at enrollment, instead of "NR"in Table 1 - which probably means "not reported", though the author did not mention its meaning.
Sexually transmitted diseases constitute a great group of diseases produced by different etiological agents, that they have in common that sexual relations are their principal line of transmission. This fact confers them the special connotation for their control we need to know and acting upon relations and sexual conducts of people. In the last 20 years, in our country has taken place a situation that complicates still mo...
AIDS collects every day more human lives, the sexual irresponsibility, poorness, the economic crises, they have converted in allies of the mortal pandemic. But I wonder: When we find the vaccine to combat this virus, would have we the possibility of putting it at the disposal of the million sick persons around the world and whose economic condition is very bad? The distribution of the antiviral medications at present i...
On Cuba we notify between 40 and 50 thousand cases annually only of Sifilis, Blenorragia and Condylomatum Acuminatum, with tendencies to the increment for years. In order to get modification of the tendencies and reduction of the transmission of these diseases, we take promotional actions of health directed to establish habits and sexual safe or minor- risk conducts, but that only we have impact in the long term, becaus...
Gaydos1 highlights the barriers to discussing sexual health issues openly and teenagers' lack of awareness of the high prevalence of STIs and potential adverse reproductive sequelae. Addressing these barriers is one solution to the 'Hidden Epidemic' of STIs. In the UK as in the USA, STI rates remain highest among sexually active teenagers, particularly those from deprived inner city areas and black ethnic minority groups....
STDs were commonly known as venereal diseases : Veneris is the Latin genitive form of the name Venus , the Roman goddess of love. Social disease was another euphemism. Public health officials originally introduced the term sexually transmitted infection , which clinicians are increasingly using alongside the term sexually transmitted disease in order to distinguish it from the former. According to Ethiopian AIDS Resourc...
Your recent major article by Harryman et al 1 assessed the performance of Aptima Combo 2 (AC2) confirmed by Aptima GC (AGC) versus culture and concluded that AC2 with AGC confirmation performed well at genital and extra-genital sites for detection of GC. Culture with transport swabs was found to perform poorly for asymptomatic men, symptomatic and asymptomatic women and at extra-genital sites. The authors conclude that c...
Stephanie Dellicour 1,2,3 , Florence Diemo4, Kayla Laserson2,3, Feiko ter Kuile1, Meghna Desai2,3 1. Child and Reproductive Health, Liverpool School of Tropical Medicine, UK 2. Kenya Medical Research Institute (KEMRI), Center for Global Health Research (CGHR), Kisumu, Kenya 3. Centers for Disease Control and Prevention (CDC), Atlanta, USA 4. Rarieda District Medical Officer for Health (DMOH), Nyanza Province, Kenya
...In a recent letter Oakeshott 1 cited the lack of data on the prevalence of Trichomonas vaginalis (TV) in young women in the UK. In their own pilot study of 183 stored self -taken vaginal samples from multi-ethnic London female students in age group of 16-27, 2 (1.1%, 95% CI 0.1%-3.9%) were positive by an in house multiplex real-time PCR test. We in Macclesfield, UK, recently conducted a prospective pilot study to ga...
Pages